Health Minister Mark Butler has challenged states and territories that have banned puberty blockers for children to comply with new national guidelines, which suggest gender-diverse teens should get access to the treatment.
The National Health and Medical Research Council (NHMRC) released an interim recommendation on Monday after the federal government launched a landmark review into the medical treatment of transgender children and adolescents in January 2025.
Labor moved swiftly to interrogate the prescription of gender transition drugs, including puberty blockers, for young people after Queensland banned them, following the United Kingdom after a health service commission found there was little scientific evidence to support the treatment.
The NHMRC recommended puberty blockers, or suppressants that delay hormonal development, be permitted across Australia for children whose gender-identity and sex recorded at birth don’t match. Prescriptions would have to be made in consultation with clinicians and parents as children begin to show physical signs of puberty.
The guideline does not require a diagnosis of gender dysphoria, the psychological distress about a mismatch of gender identity, to get treatment.
The review acknowledged the low-certainty evidence for puberty blockers, but said guidelines must be provided for best practice. It noted the treatments were reversible.
The council’s recommendation puts the Liberal government in Queensland and the Northern Territory, where bans on puberty blockers are in place, at odds with national guidelines, though the recommendation is not enforceable.
Butler said all state governments had a responsibility to ensure the highest-quality care for all Australians.
“I’m very confident that those state governments running these services will consider this advice very closely and make sure that their services are aligning with it,” Butler told reporters in Canberra.
“I know traditionally, state governments of both political persuasions have always paid high regard to the advice of the National Health and Medical Research Council.”
Butler emphasised the “unimpeachable reputation” of the NHMRC, which has set medical guidelines for decades. But those calling for a ban say there is not enough evidence the treatment is safe.
“I have the utmost respect for the National Health and Medical Research Council, and I think the role that it has long played in this country at arm’s length from the government of the day and the political process to provide the highest quality clinical advice to health practitioners and the community generally should always be respected,” Butler said.
“That’s why I asked them to try and review the evidence, and issue some pre-eminent guidelines to guide this contested, evolving area that’s the subject of so much public commentary and involves some of our most vulnerable members of the community.”
Queensland’s health minister, Tim Nicholls, rejected the new guidelines, saying the state government had made a clear decision on the provision of treatment based on its own independent review.
“Our position remains unchanged, and we will continue to prioritise the health, safety and wellbeing of young Queenslanders,” he said.
The state’s LNP government announced a ban in January last year on all publicly funded hormone treatments, including puberty blockers, for children under 18.
The ban sparked a legal brawl between the parent of a transgender teenager and the government, with Nicholls using his ministerial powers to reinstate the ban after a Supreme Court judge ruled in favour of the parent.
A class action against the ban was also launched in June.
New Zealand’s High Court last month struck down the national ban on puberty blockers, ruling that it amounted to unjustified discrimination and had not been subject to sufficient consultation.
Butler on Monday acknowledged the UK Cass review had sharpened public debate in Australia. But he said the UK context was different, and was influenced by “pretty questionable private prescribing practices” and a less multidisciplinary model of care to Australia.
The nation’s largest gender clinic, in Melbourne, prescribed 64 young people puberty suppressants in eight years, with an average wait of 530 days, Butler said.
The NHMRC advice on puberty blockers is an interim guideline ahead of its broader recommendations on gender-affirming care such as the prescription of hormones, expected in 2028.
Cut through the noise of federal politics with news, views and expert analysis. Subscribers can sign up to our weekly Inside Politics newsletter.
